|
|
|
18.07.25 - 14:00
|
Daiichi Sankyo and AstraZeneca′s Enhertu gains breakthrough therapy status (PBR)
|
|
|
This designation is for its use in combination with pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive breast cancer. The FDA's decision was
The post Daiichi Sankyo and AstraZeneca's Enhertu gains breakthrough therapy status appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
07.05.25 - 08:36
|
Enhertu improved pCR in early-stage breast cancer (Cision)
|
|
|
07 May 2025
Enhertufollowed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial
AstraZeneca and Daiichi Sankyo's Enhertu followed by THP
showed an improved safety profile vs. standard of care
First Phase III trial to demonstrate benefit of Enhertu in early breast cancer
Positive high-level results from the DESTINY-Breast11 Phase III trial showed Enhertu (trastuzumab deruxtecan) followed by paclitaxel,...
|
|
|
|
|
|
|
22.04.25 - 08:01
|
Enhertu combination improved PFS in 1L HER2+ mBC (Cision)
|
|
|
This announcement contains inside information
22 April 2025
Enhertu plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2-positive metastatic breast cancer
DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo's Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care
Positive high-level results from...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
